BioCentury
ARTICLE | Targets & Mechanisms

KOR-recting MS

Why the MS field might invest in biased opioid agonists

September 15, 2016 7:00 AM UTC

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and preclinical development. Now, two independent groups have added the kappa opioid receptor (KOR) to the list of targets, showing activation of kappa receptors in mouse models of MS triggers production of oligodendrocytes, the cells that make myelin, boosting myelin repair and recovery of muscle function.

But while the obvious challenge will be avoiding the psychotropic side effects of activating the kappa receptor, the results might be relevant beyond the receptors themselves, shedding a light on the control of myelination to inform other strategies. ...